AgeX Therapeutics Inc (AGE)

[ahab333]

Both are very good reasons for keeping the share price down but it's already increased from 2.55 to where we are now and that was almost a 30% jump for us so somebody knows something or I could just very well could be wrong but I'm holding my shares for a good while since I think they will be successful probably 2020 so GLTU and thank you for replying 2loaves

HCIT

[bobby2loaves]

Ahab, the secrecy may be less ludicrous than you think. I can come up with a couple reasons why AGE might want to keep a lid on anything good currently happening:

1. Competition - I know for a fact Michael West does not like to reveal too much about what he's working on, because it gives competitors a glimpse into potential solutions.

2. Share Price Management - Sure, you and I would like for the stock to appreciate Monday morning, as that's cash in the bank for us. But consider the position of guys like Mike West, Greg Bailey and John Mauldin. They directors only have around 100k-200k of shares/options each in this brand spanking new company. If it turns out the company is worth more than today's share price, it would be in their interest to keep that under wraps for as long as possible, so they can pick up some 10-year options on the cheap here. And JUV is obviously in this for the long haul as well, so no great benefit to a near-term share price rise here for them, especially before their IPO due sometime this year, where presumably many would benefit from getting inexpensive shares before it hits the market. Plus, AGE seems loathe to issue any shares whatsoever at this point, so no reason to get the share price up for that. And in fact, I could even see AGE getting private funding from JUV or another private investor, either of whom would probably like the share price low as well.

[ahab333]

Bobby2, it's surely a shame things are so quiet here and for all of them to purposely keep secret about what's going on or what's not going on, to me, it's ludicrous to do that especially since they own most of the shares and I would think they'd like to have their investment increase, don't you?

Let's see where shares of AGE top out and whether shares consolidate or retreat 1/2 of the 50% rise this last week or so - GLTU

HCIT

[bobby2loaves]

AGE is a black box. I don't think hardly anyone knows what's really going on there, except for its inner circle. That said, if you add up the shares of Juvenescence, Broadwood Capital, Biotime, company insiders and recent option executors, it accounts for about 80% of shares held. So its inner circle is about as large as you will find. As for the 50% share price drop in May, and the 50% share price increase in June, I would say traders used the disappointment of the reduced programs mentioned in the 1Q19 quarterly report to send the stock down, and then traded it back up knowing all the 1Q19 quarterly report really did was tell us AGE is going to be even more mysterious than it already was. AGE looks like either a zero or hero to me. Either management's silence is because nothing is going on, or because there is a lot going on that they don't want to share with others. Personally, I don't think Mike West, Jim Mellon and Greg Bailey all threw in their lot (and $50mm) with AgeX to have it fall apart in the first year. Also notice they haven't had a single share offering since going public in late 2018, and they haven't hyped a single thing about the company: no big press releases, no videos, no conference call.....just a nearly information-less quarterly report. What would you rather see? Mike West, Aubrey de Grey and Russell Skibsted making the rounds, pitching the company and raising money through share offerings? Or a company keeping its head down and efforts secret?

[ahab333]

Does anybody know why AGE is up to $3.81 from $2.55 back on May 29th this year? This is a huge move but I don't see any SEC filings nor any news and 1/4ly report isn't due out til August I believe - GLTA

HCIT

[JBZ]

Gm and happy Memorial Day to all who lost military members of family and friends. Navy and Army vet here. Was just wondering if there were anything I should worry about here such as notes, fundraisers, etc. TiA

Ps
Already read about having 12 months of operation until they will need additional funding.

[ahab333]

I agree Cinci, it's laboring to not hear what we should be hearing from West and his cronies. I too am waiting for the next Q to see if they decide to reveal more to those that support AGE, BTX especially since I'm invested in both and added a bit more this morning at 2.80 for AGE but now sorry I didn't wait til it probably goes back to dbl bottom at 2.45, we'll see - GLTU

HCIT

[Cincinnatus]

Definitely a "freak me out" quarterly report.

If you are looking for transparency, you came to the wrong place. This whole BTX, AST, AGE, OCX, Juvenescence cadre seems to be admitting they've been having fun going to Science meetings and preaching lots of far out theories, but focusing on actual products that they can turn into revenue producing entities isn't as much fun. And they sure as hell are going to keep shareholders in the dark as long as they can because if they actually give us specifics with timelines and milestones...someone might start holding them accountable...the theory stuff and "what ifs" is a much easier way to earn your salary.

I'll wait until August reports with my small BTX and AGE positions, but if they don't start reporting as if they are a commercial enterprise rather than a science experiment, I'm gone.

[bobby2loaves]

OK - I went through the quarterly filing. Here's the part that must have freaked everyone out:

Based on its cash and cash equivalents as of March 31, 2019, AgeX has made certain adjustments to its operating plans and budgets to reduce its projected cash expenditures in order to extend the period over which it can continue its operations with its available cash resources. Some of these adjustments will entail the deferral of certain work on the development of AgeX’s product candidates and technologies, which is likely to delay progress in those research and development efforts. Based on AgeX’s most recent projected cash flows AgeX believes that its cash and cash equivalents of $8.6 million as of March 31, 2019 provide sufficient cash, cash equivalents, and liquidity to carry out AgeX’s operations through at least twelve months from the issuance date of the consolidated financial statements included herein. AgeX will need to obtain substantial additional funding in connection with its continuing operations after that date. If AgeX is unable to raise capital when needed or on attractive terms, AgeX would be forced to further delay, reduce or eliminate its research and development programs.

[ahab333]

Michaael West will be presenting on Age-X Saturday April 6th in London

AgeX Therapeutics To Present At Master Investor Show 2019
AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, announced today that the company will participate at Master Investor Show 2019, in association with Fidelity International, on Saturday,...

By Business Wire
Apr 5, 2019 8:00 AM EDT

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, announced today that the company will participate at Master Investor Show 2019, in association with Fidelity International, on Saturday, April 6 in London, England. Details of the company's participation follow: Date and venueSaturday, April 6, Business Design Centre, 52 Upper Street, London 11:40-11:50am GMT - Rising Stars StageAgeX's founder and CEO, Michael D. West, Ph.D. will deliver a presentation on the company's technology and an update on its product development. 4:15-4:45pm - Panel Session: Investing in the Age of LongevityDr. West and AgeX's VP, New Technology Discovery, Aubrey de Grey, Ph.D. will serve on the panel, alongside AgeX's Chairman Gregory Bailey, M.D., who also serves as CEO of Juvenescence, a significant shareholder of AgeX. Master Investor Show is co-hosted by Jim Mellon, Chairman of Juvenescence. A copy of Dr. West's presentation will be made available on the AgeX website. About AgeX Therapeutics AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem ® and UniverCyte ™ manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a whole host of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX's revolutionary longevity platform named induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem ® is AgeX's delivery technology to stably engraft PureStem cell therapies and slowly release iTR molecules in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications. For more information, please visit www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube. Forward-Looking Statements Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates" should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the "Risk Factors" section of AgeX's Annual Report on Form 10-K filed with the Securities and Exchange Commissions (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Copyright Business Wire 2010

GLTA

[ahab333]

I was thinking the same thing but I guess that the distribution of shares for both including Asterias have made the quarterly's late IMO - GLTU

HCIT

[Cincinnatus]

Are we in business? Are we going to have a quarterly report before the next quarter starts? Same for OCX? Getting a little impatient here.

[ahab333]

LINK: https://agexinc.gcs-web.com/static-files/c81b3b2b-022a-4d4c-8ecd-e526569a225c

8K on CFO Russell Skibsted

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549FORM 8-KCURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934Date of Report (date of earliest event reported): March 1, 2019AgeX Therapeutics, Inc.(Exact name of registrant as specified in its
charter)Delaware1-3851982-1436829(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)1010 Atlantic Avenue Suite 102Alameda, California 94501(Address of principal executive offices)[phone](Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

?Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

?Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

?Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))?Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).Emerging growth company

?If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
? forward-Looking StatementsAny statements that are not historical fact (including, but not limited to statements that contain words such as “may,” “will,” “believes,” “plans,”“intends,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Additional factors that could cause actual results to differ materially from the results anticipated in these forward-looking statements are contained in AgeX’s periodic reports filed with the SEC under the heading “Risk Factors” and other filings that AgeX may make with the Securities and Exchange Commission. Undue reliance should not beplaced on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change. Except as required by law, AgeX disclaims any intent or obligation to update these forward-looking statements.References in this Report to “AgeX,” “we” or “us” refer to AgeX Therapeutics, Inc.Section 1 - Registrant’s Business and Operations Item 1.01 - Entry into a Material Definitive Agreement.Effective March 1, 2019, we entered into a compensation agreement with our Chief Financial Officer Russell Skibsted pursuant to which we have agreed to provide him the compensation described in Item 5.02 of this Report, which is incorporated into this Item 1.01 by reference Section 5 - Corporate Governance and Management Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

We have entered into a Compensation Agreement with our Chief Financial Officer Russell Skibsted pursuant to which we have agreed to pay Mr.Skibsted a one-time retention payment of $18,465.38, and then $1,500 per week for one day of services per week. Services in excess of one day per week shall be compensated at the rate of $175 per hour. Mr. Skibsted will not participate in our employee retirement, health insurance, vacation, sick leave or other employee benefit plans.Previously, Mr. Skibsted also served as the Chief Financial Officer of our former parent company BioTime, Inc. and was compensated by BioTime and participated in BioTime employee benefit plans. We did not compensate Mr. Skibsted directly for his services as our Chief Financial Officer but instead reimbursed BioTime for a portion of Mr. Skibsted’s BioTime compensation allocable to services performed for us under our Shared Facilities and Services Agreement with BioTime. The foregoing description of the terms of Mr. Skibsted’s Compensation Agreement is a summary only and does not purport to be complete. A copy of Mr. Skibsted’s Compensation Agreement will be filed as an exhibit to our Quarterly Report on Form 10-Q for the three months ending March 31, 2019.Item 8.01 – Other Events Pursuant to a Warrant Agreement, dated February 28, 2018, AgeX has set 5:00 p.m. New York time on March 18, 2019 as the expiration date of AgeX’s outstanding common stock purchase warrants (“Warrants”). The Warrants entitle Warrant holders to purchase shares of AgeX common stock at a price of $2.50 per share until the expiration date. A total of 2,000,000 Warrants are issued and outstanding.2
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the under signed here unto duly authorized.AGEX THERAPEUTICS, INC.Date: March 7, 2019By:/s/ Russell Skibsted Chief Financial Officer3

GLTA

HCIT

[bobby2loaves]

AGE Looking for Partners

For the past 2 months, AGE has been ending its press releases with the following sentence. I think this is why they haven't tried to drum up capital with share offerings, or through the spinoff: "AgeX is aggressively developing its core product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications."

I think this may be one of the benefits of having Juvenescence with a 40%+ stake in the company. They might rather sell off small pieces of the company's short-term projects (at a premium) than dilute the entire company (with the market forcing the share price down in anticipation of share placements) and preserve the holy grail of iTR undiluted. It's not been Mike West's style lately to play like this, but if I am guessing right about what's happening here, I think it's genius.

[stocktrademan]

AGE buy 4.00



normal chart







log chart

[thefamilyman]

I wonder when they will change the name on this board?

[ahab333]

I could be wrong but if I remember, it's next generation sequencing but haven't done research on it related to other bio techs if they're using this tech. Sorry that I didn't respond quicker - GLTU

HCIT

[thefamilyman]

From www.Illumina.com...

“The massively parallel sequencing technology known as next-generation sequencing (NGS) has revolutionized the biological sciences. With its ultra-high throughput, scalability, and speed, NGS enables researchers to perform a wide variety of applications and study biological systems at a level never before possible.

Today's complex genomic research questions demand a depth of information beyond the capacity of traditional DNA sequencing technologies. Next-generation sequencing has filled that gap and become an everyday research tool to address these questions.”

[thefamilyman]

Am I the only investor in the world who does not know what NGS stands for?

[ahab333]

News out on AGE

LINK: https://www.otcmarkets.com/stock/AGE/news/story?e&id=1256963

LifeMap Sciences, Tianjin Novogene and Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to the China Market

Novogene Tianjin to offer end-to-end sequencing through interpretation and reporting by integrating LifeMap’s leading TGex Clinical NGS tertiary analysis platform with their sequencing and bioinformatics services in China
Partnership to expand LifeMap’s access to the Chinese Market

ALAMEDA, Calif.--(BUSINESS WIRE)-- LifeMap Sciences, Inc., a subsidiary of AgeX Therapeutics, Inc. (NYSE American: AGE) announced today that Tianjin Novogene Medical Laboratory, LifeMap, and Shanghai Shanyi today announced a partnership to provide a combined, best-of-breed Clinical NGS analysis and interpretation platform for Tianjin Novogene Medical Laboratory’s customers in China.

LifeMap Sciences’ TGex is the leading provider of tertiary NGS analysis and interpretation solutions for rare pediatric disorders in the China market. It is today the clinical genetics solution of choice for top tier pediatric and maternal hospitals, including Peking Union Medical Center, Beijing Children’s Hospital, Shanghai International Children’s Medical Center, Shenzhen Maternal Hospital and Guanxi Maternal Hospital amongst others, as well as in private labs. TGex is distributed in China by Shanghai Shanyi, which provides molecular technologies, services and solutions throughout the territory.

“We’re very excited about this partnership,” says Yaron Guan Golan, Chief Executive Officer at LifeMap Sciences. “Novogene Tianjin is a top tier provider of sequencing and bioinformatics solutions in China and we are honored to have them select us to provide TGex as part of their bioinformatics platform. The partnership with Novogene Tianjin will allow us to rapidly expand our offerings in the China market, and together to offer best-of-breed end-to-end clinical NGS solutions to the China market.”

“We’re proud to cooperate with Novogene and LifeMap,” said Lei Li, GM at Shanghai Shanyi. “Both of them are top providers of genomic services and solutions. The NGS interpretation marketing is rapidly growing in China today as cost of sequencing decreases. This cooperation between Novogene, LifeMap, and Shanghai Shanyi will improve the quality of genetic diseases diagnosis and, potentially, treatment throughout China.”

Questions regarding the above can be directed to Mr. Lei Li at [e-mail] or to Yaron Guan Golan, CEO at LifeMap Sciences, at [e-mail].

About Novogene Tianjin Medical Laboratory

Novogene Tianjin Medical Laboratory is a CAP accredited clinical lab that provides high quality sequencing services to 1,920 scientific research institutes and universities, 720 hospitals, as well as 1,430 pharmaceutical and agricultural laboratories.

For more information, visit https://en.novogene.com/.

About LifeMap Sciences

LifeMap Sciences is a life sciences technology company that offers integrated, streamlined solutions that empower life scientists worldwide to conduct cutting-edge basic, clinical and applied biomedical research. LifeMap’s products are used in more than 3,000 institutions including academia, research hospitals, patent offices, and leading biopharma and diagnostic companies. Operations worldwide are carried out from our offices in California, Massachusetts, New Jersey, Tel Aviv, and Hong Kong. LifeMap is a subsidiary of AgeX Therapeutics, Inc.

For more information, please visit http://www.lifemapsc.com/.

About Shanghai Shanyi Biological technology

Shanghai Shanyi is a leading provider of molecular technology service and solutions, including NGS interpretation, variant validation services, DNA Extraction solutions, dedicated in improving the molecular medical service quality in China.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem® and UniverCyte™ manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a whole host of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform named induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem® is AgeX’s delivery technology to stably engraft PureStem cell therapies and slowly release iTR molecules in the body. AgeX is aggressively developing its core product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications.

For more information, please visit www.agexinc.com or connect with the company on Twitter, Facebook and YouTube.

Forward-Looking Statements

Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the “Risk Factors” section of AgeX’s Information Statement filed as an exhibit to its Registration Statement on Form 10 with the Securities and Exchange Commissions (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20190110005267r1&sid=acqr7&distro=nx&lang=en

View source version on businesswire.com: https://www.businesswire.com/news/home/20190110005267/en/

Media Contact for AgeX:
Bill Douglass
Gotham Communications, LLC
[e-mail]
[phone]

Source: AgeX Therapeutics, Inc.

© Copyright Business Wire 2019

[RLBTrader]

AGE will open close to $3.00 tomorrow. When $3.00 Falls will move to $3.25 fairly quickly.

[RLBTrader]

Nice move today with AGE. Should see follow thru on Monday. Way oversold. This low floater can move when properly motivated.

[ahab333]

I don't. The company must have been initially listed as Adventure Gold so I expect that will change soon & possibly with a CUSP# change also, we'll find out for sure.

My shares appeared yesterday and have remained there so far.

Why are shares jumping today up 102%? I've looked on the AGE website and don't see anything so far to show why it's up around 5.50/share and volume is over a mil. Can't figure out what shares are OS &
AS but a lot of volume for being on the exchange for just 2 days so far -

GLTU newguy

HCIT

[newguy49]

Well this sucks, my shares that I saw in my schwab account seem to have been pulled back. called schwab and they couldn't say why but that I should receive my shares before too long.
P.S. Does anyone know why they are calling this board Adventure gold inc

[ahab333]

Why was AGE halted twice today and now the jump up in shares to over 5 bucks?


GLTA

HCIT

[ahab333]

Mine too, yesterday but the now the value of shares in my account are correct where this morning with TD Ameritrade it showed me down 8,000 dollars, glad they corrected it to mark what the shares are to value

GLTU newguy

HCIT

[newguy49]

yep,they showed up in my account yesterday.

[pymadams]

Did you anyone see the AGEX shares appear in their brokerage account?

[DeepDive]

Welcome Agex Spinnoff.
More discussion on Biotime board BTX